We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ILLUCCIX (Telix Pharmaceuticals (ANZ) Pty Ltd)
Product name
ILLUCCIX
Date registered
Evaluation commenced
Decision date
Approval time
213 (255 working days)
Active ingredients
Glu-urea-Lys(ahx)-hbed-CC
Registration type
EOI
Indication
for the selection of patients with metastatic prostate cancer in whom lutetium Lu 177 vipivotide tetraxetan PSMA-directed therapy is indicated.